Nurix Therapeutics (NASDAQ:NRIX) Issues Quarterly Earnings Results

Nurix Therapeutics (NASDAQ:NRIX) announced its earnings results on Wednesday. The company reported ($0.82) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.84) by $0.02, FiscalAI reports. The company had revenue of $13.58 million for the quarter, compared to the consensus estimate of $13.41 million. Nurix Therapeutics had a negative net margin of 314.90% and a negative return on equity of 60.99%.

Nurix Therapeutics Trading Down 1.6%

Shares of Nurix Therapeutics stock opened at $17.59 on Friday. The firm has a fifty day simple moving average of $18.50 and a 200-day simple moving average of $13.34. The stock has a market capitalization of $1.35 billion, a price-to-earnings ratio of -5.79 and a beta of 1.93. Nurix Therapeutics has a 1-year low of $8.18 and a 1-year high of $22.50.

Analyst Upgrades and Downgrades

NRIX has been the topic of several research analyst reports. Wall Street Zen cut Nurix Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Saturday, October 11th. Piper Sandler boosted their price objective on shares of Nurix Therapeutics from $32.00 to $35.00 and gave the company an “overweight” rating in a research report on Thursday. Mizuho lifted their price objective on Nurix Therapeutics from $24.00 to $30.00 and gave the company an “outperform” rating in a research report on Wednesday, December 10th. Needham & Company LLC reaffirmed a “buy” rating and issued a $26.00 target price on shares of Nurix Therapeutics in a research report on Thursday. Finally, Royal Bank Of Canada raised their price target on Nurix Therapeutics from $28.00 to $30.00 and gave the stock an “outperform” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $29.50.

Key Stories Impacting Nurix Therapeutics

Here are the key news stories impacting Nurix Therapeutics this week:

• Positive Sentiment: Analyst upgrade: Royal Bank of Canada raised its price target to $30 and assigned an “outperform” rating, implying substantial upside vs current levels. Benzinga
• Positive Sentiment: Analyst confirmations: BTIG reaffirmed a “buy” rating with a $30 target, and Needham reaffirmed a “buy” with a $26 target — both signal continued analyst confidence in share appreciation. Benzinga
• Positive Sentiment: Clinical & corporate update: Nurix began dosing first patients in the DAYBreak™ registrational program for bexobrutideg in relapsed/refractory CLL, presented supportive Phase 1 data at ASH 2025 (reported 83% ORR and 22.1?month PFS), disclosed differentiated preclinical data for IRAK4 degrader GS?6791 with Gilead, and ended the quarter with ~$592.9M in cash and marketable securities — items that materially improve execution and runway prospects. Corporate Update
• Neutral Sentiment: Quarterly results were mixed: NRIX reported a $0.82 loss per share, slightly better than consensus (-$0.86) and revenue of $13.58M vs. ~$13.41M expected — a modest beat on the headline numbers, but the company remains unprofitable with large negative margins. Press Release
• Negative Sentiment: Conflicting coverage: Zacks ran a headline framing the quarter as a loss that “misses revenue estimates,” which may create investor confusion despite the company-reported slight revenue beat — such mixed messaging can pressure the stock near earnings. Zacks

Insider Buying and Selling

In other Nurix Therapeutics news, CFO Houte Hans Van sold 6,284 shares of the business’s stock in a transaction on Monday, November 3rd. The shares were sold at an average price of $12.56, for a total transaction of $78,927.04. Following the completion of the transaction, the chief financial officer owned 37,592 shares of the company’s stock, valued at $472,155.52. The trade was a 14.32% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 7.40% of the stock is owned by company insiders.

Institutional Investors Weigh In On Nurix Therapeutics

Several hedge funds have recently modified their holdings of NRIX. Tower Research Capital LLC TRC increased its position in Nurix Therapeutics by 118.3% during the second quarter. Tower Research Capital LLC TRC now owns 6,413 shares of the company’s stock worth $73,000 after acquiring an additional 3,475 shares during the period. Legal & General Group Plc grew its position in Nurix Therapeutics by 6.5% in the 2nd quarter. Legal & General Group Plc now owns 62,420 shares of the company’s stock worth $711,000 after purchasing an additional 3,801 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Nurix Therapeutics by 0.9% during the 3rd quarter. Dimensional Fund Advisors LP now owns 430,962 shares of the company’s stock worth $3,982,000 after purchasing an additional 3,891 shares during the period. Wexford Capital LP bought a new position in shares of Nurix Therapeutics during the 3rd quarter worth about $41,000. Finally, JPMorgan Chase & Co. raised its position in shares of Nurix Therapeutics by 10.5% during the second quarter. JPMorgan Chase & Co. now owns 50,482 shares of the company’s stock valued at $575,000 after buying an additional 4,792 shares during the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that harness the ubiquitin-proteasome system to selectively degrade disease-causing proteins. By modulating E3 ubiquitin ligases and related molecular machinery, Nurix aims to expand treatment options for patient populations with unmet medical needs in oncology and immunology.

The company’s pipeline includes multiple programs in various stages of development.